Abstract: In order to explore the efficacy and safety of albumin paclitaxel combined with tegafur (AS) regimen and albumin paclitaxel combined with gemcitabine (AG) regimen in the treatment of unresectable pancreatic cancer,patients with unresectable advanced pancreatic cancer who received AS regimen (24 cases) and AG regimen (16 cases) were selected as study subjects.Objective response rate,overall survival,progression-free survival and the incidence of grade 3/4 adverse reactions were compared between the two groups.The results showed that the objective response rate,median survival time and median progression-free survival time in AS group were higher than those in AG group,and there was no statistical significance between groups (P>0.05).The incidence of grade 3/4 peripheral nerve toxicity in AS group was significantly lower than that in AG group,and the difference was statistically significant (P<0.05).The incidence of grade 3/4 platelet count decrease,leukopenia,hemoglobin level decrease,infectious fever,nausea/vomiting,liver function impairment and poor appetite in AS group was lower than that in AG group,and the difference was not statistically significant (P>0.05).In the treatment of unresectable pancreatic cancer,the AS regimen has a lower risk of adverse effects.

Key words: pancreatic cancer, albumin paclitaxel, Tegafur,Gimeracil and Oteracil, gemcitabine